Poll: 1 in 3 ACA Marketplace Enrollees Say They Would “Very Likely” Shop for a Cheaper Plan If Their Premium Payments Doubled; 1 in 4 Say They “Very Likely” Would Go Without Insurance

If the amount they pay in premiums doubled, about one in three enrollees in Affordable Care Act Marketplace health plans say they would be “very likely” to look for a lower-premium Marketplace plan (with higher deductibles and co-pays) and one in four would “very likely” go without insurance next year, finds a new survey of…

Read More

Tanay Tandon, Commure

Tanay Tandon is CEO of Commure, which is essentially a startup conglomerate which includes the original Commure, Tanay’s company Athelas, ambient scribe Augmedix, the Strongline staff safety product, Memora Health’s workflows and more. HCA, the big for-profit chain, is one of the biggest customers and an investor in Commure. I grabbed Tanay at HIMSS earlier…

Read More

Links

Sanofi joins 340B lawsuit. Kaiser behavioral health workers on strike. Apologia of PBMs. Status of brain-computer interfaces.  How old is the moon?

Read More

Northern California Mental Health Services for Veterans: Cost-Effective Solutions

[Sponsored] Transitioning from military to civilian life can be overwhelming, especially for veterans facing mental health challenges, such as post-traumatic stress disorder (PTSD), depression or substance use disorders. The most affordable mental health treatment programs for veterans in Northern California offer affordable and specialized care tailored to veterans across the state. The post Northern California…

Read More

Pharmacists Embrace Provider Status in Healthcare, but Hurdles Remain

Despite the evidence of their positive impact, pharmacists today lack the ability to reliably bill for clinical services as healthcare providers. It is important that payers provision pharmacists, include them in networks, and enable reimbursement through traditional billing models. The post Pharmacists Embrace Provider Status in Healthcare, but Hurdles Remain appeared first on MedCity News.

Read More

Fatal Complication of Stem Cell Transplants Gets Its First FDA-Approved Therapy

Omeros’s complement system drug Yartemlea is now FDA approved for treating a severe and potentially fatal complication of hematopoietic stem cell transplants. Our recap of other regulatory actions includes drug approvals in cancer, rare disease, and metabolic disorders. The post Fatal Complication of Stem Cell Transplants Gets Its First FDA-Approved Therapy appeared first on MedCity…

Read More